- | Recce Pharmaceuticals
President’s visit proof Triangle is on the cutting edge of pandemic research
The so-called ‘synthetic anti-infectives’ are from an Australian company called ‘Recce Pharmaceuticals.’ It hopes the drugs will stop secondary bacterial infections in COVID-19 patients which it says causes the most deaths in those patients and claim that unlike most antibiotics their anti-infectives are resistant to bacterial mutations.
- | Valneva
Initial Results Positive For Valneva/Pfizer’s Lyme Disease Vaccine In First Phase II Study
Speciality vaccine biotech Valneva outlines seroconversion rates and safety of candidate Lyme disease vaccine that it is co-developing with partner Pfizer.
- | Check-Cap
Making Colorectal Cancer Screening Less of a Pain in the Ass
Colorectal cancer is the third most common form of the cancer. While screening is an effective means of preventing it, many people fail to get a colonoscopy because of the invasive nature of the procedure and the preparation and sedation that goes with it. Check-Cap is a clinical-stage company developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. The capsule uses ultra-low dose X-ray and wireless communication technologies to generate information on the contours of the inside of the colon as it passes through it. This creates a 3D map that allows physicians to look for polyps and other abnormalities. We spoke to Alex Ovadia, CEO of Check-Cap, about colorectal cancer, why people avoid being screened as they should, and how the company’s C-scan capsule-based system works.
- | Recce Pharmaceuticals
RECCE PHARMA: A NEW FRONTIER IN THE FIGHT AGAINST AMR
Antimicrobial resistance is a looming threat for modern medicine, but Australian biotech Recce Pharmaceuticals might have found a solution in its broad-spectrum synthetic antibiotic. Chloe Kent speaks to Recce executive director of regulatory affairs Michele Dilizia about the idea behind this novel approach.
- | Sotio
Immunocytokines Platform Superagonist Activates T-cells and NK Cells to Fight Solid Tumors With Jens Hennecke SOTIO
Jens Hennecke, Chief Business Officer, SOTIO explains how this biotech company is developing the next generation of immunotherapies with a focus on a new compound called SO-C101 based on the cytokine IL-15, the key cytokine that activates T-cells and NK cells. In clinical trials, this drug, a modified IL-15 does not cause unwanted side effects like similar products to treat solid tumors and is a superagonist with a much better potency to activate memory T-cells, cytotoxic T-cells and NK cells.
- | Chiasma
New FDA-Approved Treatment Could Mean End to Painful Shots For Acromegaly Patients
There is new hope for people with acromegaly, a rare disorder that involves painful injections. A new FDA-approved treatment could mean daily pills instead of shots. NBC 5’s Lauren Petty reports.
- | Cerevance
Biotech Startup Cerevance Extends Series B to $65 Million
Investors have boosted biotech startup Cerevance Inc.’s Series B financing to $65 million, powering its search for new approaches to battling neurological diseases. Cerevance, based in Boston, set out in January to raise $60 million. By late March, however, the company had elected to lock in the first $45 million, due to the upheaval caused by the coronavirus pandemic. In April, it held a first closing on that amount, Chief Executive Brad Margus said
- | Acepodia
Acepodia: linking antitumor antibodies to immune cells
Acepodia is using its antibody-cell conjugation platform to link tumor-targeting antibodies to the surface of cell therapies while avoiding genetic engineering. The platform, which has the potential for cost savings compared with CAR T therapy, led JW Therapeutics to partner with the company for commercialization of its lead program Tuesday.
